2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%

News
Sep.23
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.

Key Points

  • China’s vape-related exports reached $979 million in August, up 3.3% year over year and down 6.4% from July.
  • UK-bound exports rose 51.4% to $177 million, adding $60.1 million and generating the largest increase among all destinations.
  • Exports to the U.S. fell 12.4% to $339 million, a decline of $48.2 million and the largest reduction among major markets.
  • Exports outside the U.S. rose 14.2%; excluding the UK as well, shipments to all other markets still increased 4.4%.

2Firsts

September 23, 2026

China’s vape-related exports continued to rise in August 2026, but the market driving that growth changed.

Exports across three vape-related customs categories reached $979 million, up 3.3% from a year earlier and down 6.4% from July, according to China Customs data released on September 18 and compiled by 2Firsts.

Exports for the first eight months of 2026 totaled $6.99 billion, an increase of 5.5% from the same period last year.

The U.S. generated about 94.9% of the year-over-year increase in July. One month later, U.S.-bound shipments declined and the UK became the largest source of growth.

UK Exports Jump 51.4% to a 2026 High

China exported $177 million of vape-related products to the UK in August, up 51.4% from a year earlier and 10.1% from July. It was the highest monthly total for the UK in 2026.

UK-bound shipments added $60.1 million from a year earlier, almost twice the $31.3 million net increase in China’s global exports. Growth in the UK offset declines in shipments to the U.S., Japan, Germany and Russia.

Both major product categories contributed:

Product CategoryAugust 2026 ExportsYear-Over-Year ChangeIncrease
Nicotine-containing vape products$82.7 million+63.3%+$32.1 million
Vape devices$94.1 million+42.1%+$27.9 million
Nicotine-substitute products$0.3 million+106.9%+$0.1 million

UK-bound exports totaled $903 million in the first eight months of 2026, up 6.4% from a year earlier. Nicotine-containing products increased 29.4%, while device exports fell 9.6%. The August surge in devices has not yet erased their cumulative decline.

The customs figures do not show whether the August increase came from retail demand, inventory replenishment or a shift in purchasing schedules.

U.S. Shifts From the Largest Contributor to the Biggest Drag

Exports to the U.S. fell 12.4% year over year and 16.1% from July to $339 million. The $48.2 million decline was the largest among all destinations.

The U.S. remained China’s largest market, accounting for 34.6% of August exports.

Product CategoryAugust 2026 U.S. ExportsYear-Over-Year Change
Nicotine-containing vape products$278 million-9.8%
Vape devices$56.7 million-24.4%
Nicotine-substitute products$4.9 million+5.6%

The drop followed a sharp increase in July, when U.S.-bound shipments reached $404 million and rose 53.5% from a year earlier.

Exports to the U.S. still increased over the longer period. Shipments totaled $2.32 billion in the first eight months of 2026, up 4.7%. Nicotine-containing products rose 1.3%, devices increased 10.4%, and nicotine-substitute products climbed 179.9%.

Growth Broadens Beyond the U.S.

Exports to markets outside the U.S. reached $640 million in August, up 14.2% from a year earlier.

Excluding both the U.S. and UK, shipments to all other destinations still increased 4.4%. In July, by comparison, markets outside the U.S. grew just 1.2%.

Beyond the UK, the largest increases came from South Korea, Croatia, Indonesia, Slovakia, Canada and the United Arab Emirates.

MarketAugust 2026 ExportsYear-Over-Year ChangeIncrease
South Korea$42.8 million+35.6%+$11.2 million
Croatia$22.4 million+77.1%+$9.7 million
Indonesia$27.7 million+47.7%+$9.0 million
Slovakia$9.2 million+1,264.1%+$8.5 million
Canada$30.8 million+21.1%+$5.4 million
United Arab Emirates$38.9 million+13.2%+$4.5 million

Exports to Japan, Germany, Russia and Poland declined. Shipments to Japan fell 44.7%, Germany dropped 24.7%, and Russia declined 34.5%.

Slovakia’s growth rate reflected a low comparison base. Customs records identify the declared destination, not the final consumer market, and do not show whether goods were subsequently distributed elsewhere in Europe.

Nicotine-Containing Products Deliver Most of the Increase

Exports of nicotine-containing vape products rose 4.9% to $666 million in August, generating nearly all of the net increase.

Device exports fell 0.7% to $299 million. Nicotine-substitute products increased 17.1% to $14.3 million.

Product CategoryAugust 2026 ExportsYear over YearMonth over Month
Nicotine-containing vape products$666 million+4.9%-7.0%
Vape devices$299 million-0.7%-4.6%
Nicotine-substitute products$14.3 million+17.1%-15.4%
Total$979 million+3.3%-6.4%

All three categories declined from July, signaling softer monthly momentum despite the year-over-year increase.

August reversed the geographic pattern seen a month earlier. U.S. growth faded, the UK became the largest source of new exports, and shipments to markets outside the U.S. accelerated. China’s vape-related exports remain in recovery, but the markets supporting that recovery continue to shift from month to month.

Data Notes

The analysis covers HS 24041200, HS 85434000 and HS 24041990.

HS 24041990 includes non-combustible inhalation products containing nicotine substitutes. China Customs data do not disclose individual ingredients, and exports under the code cannot be treated as synonymous with products containing 6-methyl nicotine.

Customs trade partners represent declared export destinations and may not be the final consumer markets. Year-over-year comparisons are against August 2025; month-over-month comparisons are against July 2026.

Follow 2Firsts for timely updates on global tobacco and nicotine industry developments, corporate strategy and market trends.

 

Cover Image: China’s Vape Export Growth Shifted From the U.S. to the UK in August 2026|visualized by 2Firsts

2FIRSTS | 2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
2FIRSTS | 2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
China’s vape-related exports reached $1.047 billion in July 2026, up 16.5% year on year and the highest monthly total of the year. Growth was heavily concentrated in the U.S., where exports jumped 53.5% to $404 million and accounted for 94.9% of the overall increase. Exports to all other markets rose just 1.2%. By category, nicotine-containing non-combustible products—primarily vapes—under HS24041200 rose 24.7% and generated 95.5% of the total increase. Vape-device exports under HS85434000 fell 0.4%, while other nicotine-substitute products under HS24041990 grew 88.9% but remained comparatively small.
www.2firsts.com

Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22